CN115813989A - Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof - Google Patents
Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof Download PDFInfo
- Publication number
- CN115813989A CN115813989A CN202211465659.5A CN202211465659A CN115813989A CN 115813989 A CN115813989 A CN 115813989A CN 202211465659 A CN202211465659 A CN 202211465659A CN 115813989 A CN115813989 A CN 115813989A
- Authority
- CN
- China
- Prior art keywords
- total
- extract
- weight
- parts
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 208000006673 asthma Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 123
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
- 150000004676 glycans Chemical class 0.000 claims abstract description 39
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 39
- 239000005017 polysaccharide Substances 0.000 claims abstract description 39
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 37
- 229930003944 flavone Natural products 0.000 claims abstract description 37
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 37
- 235000011949 flavones Nutrition 0.000 claims abstract description 37
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 150000007965 phenolic acids Chemical class 0.000 claims abstract description 35
- 244000185386 Thladiantha grosvenorii Species 0.000 claims abstract description 14
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims abstract description 14
- 235000013372 meat Nutrition 0.000 claims abstract description 13
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 7
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 7
- 244000277583 Terminalia catappa Species 0.000 claims abstract description 7
- 235000011517 Terminalia chebula Nutrition 0.000 claims abstract description 7
- 240000001090 Papaver somniferum Species 0.000 claims abstract description 6
- 235000008753 Papaver somniferum Nutrition 0.000 claims abstract description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 6
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 6
- 241000018646 Pinus brutia Species 0.000 claims abstract description 6
- 241001233061 earthworms Species 0.000 claims abstract description 5
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 4
- 235000020638 mussel Nutrition 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 241000361919 Metaphire sieboldi Species 0.000 claims description 5
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 108090000526 Papain Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 3
- 150000002215 flavonoids Chemical class 0.000 claims description 3
- 235000017173 flavonoids Nutrition 0.000 claims description 3
- 238000000703 high-speed centrifugation Methods 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 235000009048 phenolic acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 9
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 230000009466 transformation Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 description 27
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 20
- 206010011224 Cough Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 229920002472 Starch Polymers 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 239000008107 starch Substances 0.000 description 12
- 235000019698 starch Nutrition 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 11
- 239000012085 test solution Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 10
- 229940074391 gallic acid Drugs 0.000 description 10
- 235000004515 gallic acid Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 7
- 238000012417 linear regression Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000011049 filling Methods 0.000 description 5
- 239000012088 reference solution Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 244000276331 Citrus maxima Species 0.000 description 3
- 235000001759 Citrus maxima Nutrition 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 3
- 230000010085 airway hyperresponsiveness Effects 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- -1 vaseline Substances 0.000 description 3
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010044302 Tracheitis Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000029771 childhood onset asthma Diseases 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 230000004676 abdominal muscle contraction Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000588 effect on asthma Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine effective part composition for treating asthma and a preparation method and application thereof, wherein the composition comprises a total polysaccharide extract, a total polypeptide extract, a total flavone extract and a total phenolic acid extract; the total polysaccharide extract is extracted from momordica grosvenori, red tangerine peel and cuttlebone, the total polypeptide extract is extracted from earthworms and mussel meat, the total flavone extract is extracted from pine pollen and poppy flowers, and the total phenolic acid extract is extracted from myrobalan meat. Experiments prove that the effective part composition has obvious synergistic effect in the aspect of treating asthma, the product has clear components, stable curative effect, small dosage and high safety, not only accords with the formula principle of treating asthma by using traditional Chinese medicines, but also accords with the development requirement of modernization of traditional Chinese medicines, and has important significance in promoting the transformation of imitation of the medicine industry to autonomous innovation and the internationalization of traditional Chinese medicines in China.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine effective part composition for treating asthma, and a preparation method and application thereof.
Background
Asthma is also called bronchial asthma, is a common disease and frequently occurs, and has the main symptoms of paroxysmal wheeze, dyspnea, chest distress and cough. Bronchial asthma is a chronic inflammatory disease of the airways involving various cells and cell components, which is associated with airway hyperresponsiveness, and is usually characterized by wide and variable reversible airflow limitation, resulting in recurrent wheezing, shortness of breath, chest tightness and cough. Epidemiological survey results show that: the prevalence rate of asthma in China is increased from 7.3% in 2001 to 8.4% in 2010, and two large-scale pediatric asthma prevalence surveys in 1990 and 2000 show that the prevalence rate of childhood asthma is increased from 0.91% to 1.54%, and is increased by 64.84% in more than one decade, and it is estimated that about 3 hundred million people worldwide suffer from asthma at present. Therefore, the treatment of bronchial asthma is not optimistic.
The western medicines for treating bronchial asthma include anti-airway inflammation medicines, bronchodilators and specific immunotherapy. The anti-inflammatory drug can inhibit and prevent the development of airway inflammation and reduce airway hyperresponsiveness; bronchodilators can relieve the symptoms of airway obstruction. However, the single use of bronchodilators is not suitable for symptomatic treatment, particularly for patients with moderate to severe asthma. Because the bronchia relax, more allergen enters the airway, and if the anti-inflammatory drug is not given for effective anti-inflammation, the airway inflammation will be aggravated continuously, which is the important reason that the illness condition can be aggravated continuously by simply using the airway spasmolytic drug for a long time. Furthermore, patients with moderate to severe asthma have different degrees of airway remodeling, and airway hyperresponsiveness is not only related to inflammation, but also related to vessel wall thickening and lumen narrowing caused by smooth muscle proliferation, so that anti-inflammatory and spasmolytic treatment must be applied at the same time to effectively control the disease condition.
The traditional medicine considers that: the lung is the main part of qi, and the kidney is the root of qi. When asthma attacks, the lung fails to control qi, and the kidney deficiency fails to receive qi, which leads to the adverse flow of qi to the upper part of the body and causes dyspnea. Spleen is the source of generation and transformation, and spleen deficiency produces phlegm, phlegm obstructs the airway, so cough and asthma, short breath are seen. Therefore, asthma is the symptom of deficiency of kidney, lung, spleen and three. The asthma is clinically divided into a remission stage and an attack stage. In the remission stage, the deficiency of the three zang organs of the lung, spleen and kidney is caused by kidney yang deficiency, and the latent internal diseases are remained, so syndrome differentiation and treatment mainly aims at tonifying the kidney and warming yang, and also has the functions of tonifying the spleen and benefiting the lung, eliminating phlegm and removing turbidity.
However, the traditional Chinese medicine decoction pieces are not easily accepted by patients due to low content of effective components, large dosage, inconvenience and bitter taste of the medicines, but the content of the effective components is improved, the dosage is reduced, the taking is convenient, good medicines are not bitter, and the accepted population is increased.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the traditional Chinese medicine effective part composition for treating asthma, and the preparation method and the application thereof, and the traditional Chinese medicine effective part composition has obvious curative effect on asthma treatment and can be applied to various preparations.
In order to realize the purposes, the adopted technical scheme is as follows:
the invention aims to provide a traditional Chinese medicine effective part composition for treating asthma, which comprises a total polysaccharide extract, a total polypeptide extract, a total flavone extract and a total phenolic acid extract;
the total polysaccharide extract is extracted from momordica grosvenori, red tangerine peel and cuttlebone, the total polypeptide extract is extracted from earthworm and mussel meat, the total flavone extract is extracted from pine pollen and poppy flower, and the total phenolic acid extract is extracted from myrobalan meat.
Further, the traditional Chinese medicine effective part composition comprises 9-20 parts by weight of total polysaccharide extract, 3-10 parts by weight of total polypeptide extract, 6-12 parts by weight of total flavone extract and 3-6 parts by weight of total phenolic acid extract.
Furthermore, the traditional Chinese medicine effective part composition comprises 12 parts by weight of total polysaccharide, 6 parts by weight of total polypeptide, 8 parts by weight of total flavone and 4 parts by weight of total phenolic acid.
Further, the content of total polysaccharide in the total polysaccharide extract is not less than 70wt%, the content of total polypeptide in the total polypeptide extract is not less than 80wt%, and the content of total flavone in the total flavone extract is not less than 40wt%.
Further, the weight ratio of the momordica grosvenori to the pummelo peel to the cuttlebone is 1: (1-3): (1-4).
Further, the mass ratio of the momordica grosvenori to the red tangerine peel to the cuttlebone is 1:1.5:1.
the invention also aims to provide a preparation method of the traditional Chinese medicine effective part composition, which comprises the following steps:
(1) Preparing a total polysaccharide extract: taking 4 parts by weight of momordica grosvenori, 6 parts by weight of exocarpium citri rubrum and 4 parts by weight of cuttlebone, adding 8-12 times of weight of water to extract for 1-3 times, each time for 2 hours, filtering, combining filtrates, concentrating under reduced pressure to 1g crude drug/mL, adding ethanol to the alcohol content of 50%, refrigerating and standing for 12 hours, filtering, continuously adding ethanol to the filtrate to the alcohol content of 80%, refrigerating and standing for 12 hours, collecting precipitate, repeatedly purifying the precipitate, adding 5-15 times of weight of water to fully dissolve, adding 0.5-5% of active carbon, keeping the temperature at 70-80 ℃ for decolorizing for 1-3 times, 0.5 hour/time, filtering, concentrating the filtrate under reduced pressure, and drying to obtain a total polysaccharide extract;
(2) Preparation of total polypeptide extract: taking 4 parts by weight of earthworms and 6 parts by weight of clam meat, adding 2-2.5 times of water by weight to homogenate to obtain meat pulp, adding 0.8% of papain, carrying out enzymolysis at 45 ℃ for 4 hours under the pH value of 6.5, after the enzymolysis reaction is finished, heating to 80-85 ℃, reacting for half an hour, standing at room temperature for 3 hours, and carrying out high-speed centrifugation at 12000r/min to obtain supernatant for spray drying to obtain a total polypeptide extract;
(3) Preparing a total flavone extract: taking 8 parts by weight of pine pollen and 2 parts by weight of poppy flower, adding 12-15 times of 70% ethanol by weight, extracting twice at 74-76 ℃ for 1.5 hours each time, concentrating the filtrate under reduced pressure, and drying to obtain a total flavone extract;
(4) Preparing a total phenolic acid extract: taking myrobalan pulp, adding 70% ethanol with the weight being 12-14 times of that of the myrobalan pulp, carrying out ultrasonic extraction for 2-3 times, combining filtrates, carrying out reduced pressure concentration, and drying to obtain a total phenolic acid extract.
The percentage of ethanol in the invention is volume percentage.
The invention also aims to provide application of the traditional Chinese medicine effective part composition in preparing a medicine for treating asthma.
Further, the four effective part extracts are taken according to the weight ratio of each effective part, and are prepared into any one of pharmaceutically acceptable dosage forms, such as tablets, granules, hard capsules, mixtures, pills, dripping pills, effervescent tablets, injections, powder injections or soft capsules without adding auxiliary materials or adding pharmaceutically conventional auxiliary materials.
The above-mentioned pharmaceutically conventional excipients include, but are not limited to, binders such as cellulose derivatives, alginates, gelatin and polyvinylpyrrolidone; diluents, starch, sugar powder, dextrin, lactose, microcrystalline cellulose, mannitol; lubricants, such as talc, magnesium stearate, aerosil and polyethylene glycol; disintegrants, such as carboxymethyl starch sodium, low-substituted hypromellose, croscarmellose; absorption promoters, such as quaternary ammonium compounds; surfactants such as cetyl alcohol, sodium lauryl sulfate; excipients, such as lactose, starch, sucrose, dextrin, calcium carbonate, aluminum sulfate, magnesium oxide, magnesium stearate, sodium bicarbonate, glycerol, propylene glycol, polyethylene glycol, sorbitol, lanolin, vaseline, microcrystalline cellulose, beeswax, wood wax, liquid paraffin, resin, higher wax, pressure sensitive adhesive, semisynthetic fatty acid ester, etc.
Compared with the prior art, the invention has the beneficial effects that:
the invention takes the traditional Chinese medicine theory as a guiding idea, and simultaneously combines related research results at home and abroad, and has remarkable effect in the aspect of treating the bronchial asthma. In the formula, the tangerine peel is a monarch drug, and is pungent, bitter and warm in nature. It enters lung and spleen meridians. Has the effects of regulating qi, relieving epigastric distention, eliminating dampness and resolving phlegm. Is used for treating cough with excessive phlegm, and the total polysaccharide in the pummelo peel has obvious effects of relieving cough and eliminating phlegm, so the pummelo peel is a monarch drug. The momordica grosvenori is a ministerial drug, is sweet in taste and cool in nature, enters lung and large intestine channels, has the effects of moistening lung to arrest cough, and engendering liquid to quench thirst, and modern medicine proves that the momordica grosvenori has a remarkable curative effect on diseases such as bronchitis and hypertension, has the effects of clearing heat, relieving summer-heat, reducing phlegm, arresting cough, cooling blood, relaxing bones, clearing lung, lubricating intestines, engendering liquid to quench thirst and the like, can treat diseases such as acute and chronic tracheitis, bronchial asthma and pertussis, and is therefore the ministerial drug. Earthworms are cold in nature. The earthworm total polypeptide can resist the bronchoconstriction caused by histamine and has immediate curative effect on the attack of bronchial asthma, so the earthworm total polypeptide is an adjuvant drug. Pollen pini is a guiding drug with sweet and warm properties, and can nourish yin to avoid damaging the body fluid and consuming qi, and harmonize the effects of the other drugs in the recipe. The medicines in the formula supplement each other, but lack one, and the formula is reasonable according to the monarch, minister, assistant and guide theory of the traditional Chinese medicine, so that the effects of clearing heat and reducing phlegm, ventilating lung and benefiting qi, descending qi and relieving asthma and benefiting lung and spleen are achieved together;
experiments prove that the effective part composition has obvious synergistic effect on the aspect of treating asthma;
the product has definite components, stable curative effect, small dosage and high safety, not only accords with the formula principle of the traditional Chinese medicine for treating asthma, but also accords with the development requirement of the modernization of the traditional Chinese medicine, and has important significance for promoting the transformation of imitation of the medicine industry to independent innovation and the internationalization of the traditional Chinese medicine in China.
Detailed Description
The principles and features of this invention are described below in conjunction with examples, which are set forth to illustrate, but are not to be construed to limit the scope of the invention. The dosage in the actual production is not limited to the dosage of the drugs in the examples, and the dosage can be measured in units of ton, kilogram, gram and the like, but the dosage proportion of the raw materials is still according to the technical scheme of the invention.
In a specific embodiment, the method for measuring the total polysaccharide content comprises the following steps: precisely weighing 10mg of glucose reference substance dried to constant weight at 105 ℃, placing the reference substance in a 100mL volumetric flask, adding distilled water to dissolve completely, fixing the volume to a scale, and shaking up to obtain a reference solution with the glucose concentration of 100 ug/mL. Precisely absorbing 0.0mL, 0.2mL, 0.4mL, 0.6mL, 0.8mL, 1.0mL, 1.2mL and 1.4mL of glucose contrast solution into a 10mL test tube with a plug respectively, adding distilled water to supplement 2.0mL, adding 1.0mL of 6% phenol solution respectively, mixing uniformly, quickly adding 5.0mL of concentrated sulfuric acid, mixing uniformly, keeping the temperature at 60 ℃ for reaction for 15min, stopping the reaction by using an ice water bath for 15min, measuring the absorbance at 490nm by taking a No. 0 tube as a reference and calculating a linear regression equation by using the concentration of the contrast solution and the absorbance corresponding to the concentration of the contrast solution. Taking 15mg of total polysaccharide effective part, placing in a 100mL volumetric flask, adding distilled water to dissolve completely, and fixing the volume to the scale. Sucking 1mL of test solution into a 10mL test tube with a plug, adding distilled water to supplement 2.0mL, respectively adding 1.0mL of 6% phenol solution, mixing uniformly, quickly adding 5.0mL of concentrated sulfuric acid, mixing uniformly, keeping the temperature at 60 ℃ for reaction for 15min, stopping the reaction by using an ice water bath for 15min, measuring the absorbance value, substituting into a standard curve, and calculating to obtain the product.
In a specific embodiment, the method for determining the total polypeptide content comprises the following steps: accurately weighing 20mg of bovine serum albumin reference substance, putting the bovine serum albumin reference substance into a 100mL measuring flask, adding distilled water to dissolve completely, fixing the volume to a scale, and shaking up to obtain a reference solution with the bovine serum albumin concentration of 0.2 mg/mL. Accurately sucking bovine serum albumin control solution 0.0mL, 0.2mL, 0.4mL, 0.6mL, 0.8mL and 1.0mL respectively, placing in a test tube with a plug, adding water to 1.0mL respectively, adding alkaline copper test solution 1.0mL respectively, shaking, standing at room temperature for 10 minutes, adding Fulinfen test solution 4.0mL respectively, mixing uniformly immediately, standing at room temperature for 30 minutes, and measuring absorbance at 650nm wavelength by ultraviolet-visible spectrophotometry; while blank tube No. 0. And calculating a linear regression equation by using the concentration of the reference solution and the corresponding absorbance. Taking 20mg of total polypeptide effective part, placing in a 100mL volumetric flask, adding distilled water to dissolve completely, and fixing the volume to the scale. Sucking 1mL of test solution into a 10mL test tube with a plug, adding 1.0mL of alkaline copper test solution, shaking uniformly, standing at room temperature for 10 minutes, adding 4.0mL of folin phenol test solution respectively, mixing uniformly immediately, standing at room temperature for 30 minutes, and measuring the absorbance at the wavelength of 650 nm. And calculating the total polypeptide concentration in the test solution from a linear regression equation, and multiplying by the dilution factor to obtain the polypeptide.
In a specific embodiment, the method for measuring the content of the total flavonoids comprises the following steps: precisely weighing rutin control substance dried at 120 deg.C under reduced pressure to constant weight of about 10mg, placing in 100mL volumetric flask, adding 70% ethanol 70mL, placing in water bath, slightly heating for dissolving, cooling, adding 70% ethanol to scale, and shaking. Precisely sucking 1.0mL, 2.0mL, 3.0mL, 4.0mL and 5.0mL of reference substance solution, respectively placing in a 10m L measuring flask, respectively adding 4.0mL, 3.0mL, 2.0mL, 1.0mL and 0mL of water, adding 0.3mL of 5% sodium nitrite solution, shaking, standing for 6min, adding 0.3m L of 10% aluminum nitrate solution, shaking, standing for 6min, adding 4mL of 4% sodium hydroxide, adding water, scaling, shaking, and standing for 12min; preparing blank solution by the same method. Absorbance was measured at 510 nm. And calculating a linear regression equation by using the concentration of the reference solution and the corresponding absorbance. Taking 30mg of total flavone effective components, adding 70% ethanol into a 100ml volumetric flask to scale, shaking up, and filtering. Precisely measuring 3mL of filtrate, adding 2mL of water, adding 0.3mL of 5% sodium nitrite solution, shaking uniformly, standing for 6min, adding 0.3mL of 10% aluminum nitrate solution, shaking uniformly, standing for 6min, adding 4mL of 4% sodium hydroxide, adding water scales, shaking uniformly, and standing for 12min. And (3) measuring the absorbance at 510nm, calculating the concentration of the total flavone in the test solution according to a linear regression equation, and multiplying the concentration by the dilution factor to obtain the total flavone.
In a specific embodiment, the method for measuring the content of the total phenolic acid comprises the following steps: accurately weighing 10.0mg of gallic acid reference substance, placing the gallic acid reference substance into a 100mL measuring flask, adding distilled water to dissolve the gallic acid reference substance, fixing the volume and shaking up to obtain a gallic acid reference stock solution, accurately sucking 10mL of the gallic acid reference stock solution, placing the gallic acid reference stock solution into the 100mL measuring flask, adding water to dilute the gallic acid reference stock solution to scale, obtaining a gallic acid reference stock solution, accurately sucking 0.0mL, 0.2mL, 0.4mL, 0.6mL, 0.8mL, 1.0mL and 1.2mL of the gallic acid reference stock solution, respectively placing the gallic acid reference stock solution into the 10mL measuring flask, adding water to 2mL, accurately adding 0.5mL of Fulin phenol reagent, shaking up, accurately adding 2mL of 10% sodium carbonate solution, shaking up, adding distilled water to fix the volume to scale, carrying out water bath at 75 ℃ for 10min, cooling to room temperature, irradiating an ultraviolet-visible spectrophotometry, and measuring the absorbance at the wavelength of 750 nm; while blank tube No. 0. And calculating a linear regression equation by using the concentration of the reference solution and the corresponding absorbance. Taking 10mg of the total phenolic acid effective part, putting the total phenolic acid effective part into a 100mL volumetric flask, adding distilled water to dissolve completely, and fixing the volume to the scale. Sucking 1mL of test solution into a 5mL measuring flask, adding water to the scale, shaking up to obtain a test solution, precisely adding 0.5mL of forinophenol reagent, shaking up, precisely adding 2mL of 10% sodium carbonate solution, shaking up, adding distilled water to fix the volume to the scale, carrying out water bath at 75 ℃ for 10min, cooling to room temperature, measuring absorbance at the wavelength of 750nm by an ultraviolet-visible spectrophotometry method, calculating the concentration of total phenolic acid in the test solution according to a linear regression equation, and multiplying the concentration by a dilution factor to obtain the compound.
Example 1
The capsule for treating asthma is prepared by the following formula: 120g of total polysaccharide extract, 60g of total polypeptide extract, 80g of total flavone extract and 40g of total phenolic acid extract.
The preparation method of the total polysaccharide extract comprises the following steps: taking 4 parts by weight of momordica grosvenori, 6 parts by weight of exocarpium citri rubrum and 4 parts by weight of cuttlebone, adding 10 times of water for 2 times, each time for 2 hours, filtering, combining filtrates, concentrating under reduced pressure to 1g crude drug/mL, adding ethanol to reach the alcohol content of 50%, refrigerating and standing for 12 hours, filtering, continuously adding ethanol to reach the alcohol content of 80%, refrigerating and standing for 12 hours, collecting precipitate, repeatedly purifying the precipitate, adding 15 times of water to fully dissolve, adding 3% of active carbon, carrying out heat preservation and decoloration at 75 ℃ for 2 times, 0.5 hour/time, filtering, concentrating the filtrate under reduced pressure, and drying to obtain a total polysaccharide extract, wherein the total polysaccharide content is measured to be 72.3%.
The preparation method of the total polypeptide extract comprises the following steps: taking 4 parts by weight of earthworms and 6 parts by weight of clam meat, adding 2.5 times of water to homogenate to obtain meat pulp, adding 0.8% of papain, carrying out enzymolysis at 45 ℃ and pH 6.5 for 4 hours, heating to 85 ℃ after the enzymolysis reaction is finished, reacting for half an hour, standing at room temperature for 3 hours, carrying out high-speed centrifugation at 12000r/min to obtain supernatant, and carrying out spray drying to obtain a total polypeptide extract, wherein the total polypeptide content is 81.5% by measurement.
The preparation method of the total flavone extract comprises the following steps: mixing 8 parts by weight of pollen Pini and 2 parts by weight of flos Papaveris, adding 15 times of 70% ethanol, extracting at 75 deg.C twice, each for 1.5 hr, concentrating the filtrate under reduced pressure, and drying to obtain total flavone extract with total flavone content of 42.0%.
Preparing a total phenolic acid extract: adding 14 times of 70% ethanol into fructus Chebulae, ultrasonic extracting for 2 times, mixing filtrates, concentrating under reduced pressure, and drying to obtain total phenolic acid extract.
The preparation method comprises the following steps: taking the above effective part extracts according to a prescription, pulverizing, mixing, adding starch to 360g, mixing, granulating, and encapsulating into No. 1 capsule, wherein each capsule contains 0.3g of content.
Example 2
The tablet for treating asthma is prepared by the following formula: 120g of total polysaccharide extract, 60g of total polypeptide extract, 80g of total flavone extract and 40g of total phenolic acid extract.
The preparation methods of the total polysaccharide extract, the total polypeptide extract, the total flavone extract and the total phenolic acid extract are the same as the example 1.
The preparation method comprises the following steps: taking the above effective part extracts according to the prescription, pulverizing, mixing, adding hypromellose 25g, microcrystalline cellulose 20g, isomalt 10g, lactose to 360g, mixing, granulating, and tabletting.
Example 3
The soft capsule for treating asthma is prepared by the following formula: 120g of total polysaccharide extract, 60g of total polypeptide extract, 80g of total flavone extract and 40g of total phenolic acid extract.
The preparation methods of the total polysaccharide extract, the total polypeptide extract, the total flavone extract and the total phenolic acid extract are the same as the example 1.
The preparation method comprises the following steps: taking the above effective components according to the prescription, adding polyethylene glycol 400 and soybean oil 30g respectively to total amount of 360g, mixing, and making into soft capsule.
Example 4
The preparation of the granules for treating asthma comprises the following steps: 120g of polysaccharide extract, 60g of total polypeptide extract, 80g of total flavone extract and 40g of total phenolic acid extract.
The preparation methods of the total polysaccharide extract, the total polypeptide extract, the total flavone extract and the total phenolic acid extract are the same as the example 1.
The preparation method comprises the following steps: taking the above effective components according to the prescription, adding 20% of starch by weight, and 90% of ethanol by weight, and granulating.
Example 5
The preparation of the granules for treating asthma comprises the following steps: 24kg of polysaccharide extract, 12kg of total polypeptide extract, 16kg of total flavone extract and 8kg of total phenolic acid extract.
The preparation methods of the total polysaccharide extract, the total polypeptide extract, the total flavone extract and the total phenolic acid extract are the same as the example 1.
The preparation method comprises the following steps: taking the above effective components according to the prescription, adding polyvidone K30 10 wt% and ethanol 90 wt%, granulating, and packaging 5g of the obtained granule per bag.
140 asthma patients were treated with the granules prepared in example 5. The treatment scheme comprises the following steps: it is administered orally 1 bag at a time, 3 times a day, and 8 weeks as a treatment course. As a result: 119 cases are improved, the obvious effect is 13 cases, the ineffective effect is 8 cases, and the total effective rate is 94.3 percent.
Comparative example 1
200g of momordica grosvenori, 120g of red tangerine peel, 60g of cuttlebone, 160g of earthworm, 120g of mussel meat, 60g of pine pollen and 100g of poppy flower are taken, 10 times of water is added for decocting for 2 hours, filtering is carried out, 8 times of water is added for decocting dregs for 1.5 hours, filtering is carried out, filtrates are combined, vacuum concentration is carried out, vacuum drying is carried out, crushing is carried out, starch is added to 360g, the mixture is filled into No. 1 capsules, 0.3g of the content in each capsule is prepared into capsules.
Comparative example 2
Taking 80g of polysaccharide extract, 80g of total polypeptide extract, 80g of total flavone extract and 60g of total phenolic acid extract prepared in the example 1, adding starch to 360g, filling into No. 1 capsules, and preparing the capsules, wherein the content of each capsule is 0.3 g.
Comparative example 3
Taking 120g of polysaccharide extract, 60g of total polypeptide extract and 80g of total flavone extract prepared in example 1, adding starch to 360g, filling into No. 1 capsules, and preparing into capsules, wherein the content of each capsule is 0.3 g.
Comparative example 4
Taking 120g of polysaccharide extract, 60g of total polypeptide extract and 40g of total phenolic acid extract prepared in example 1, adding starch to 360g, filling into No. 1 capsules, and preparing into capsules, wherein the content of each capsule is 0.3 g.
Comparative example 5
Taking 120g of polysaccharide extract, 80g of total flavone extract and 40g of total phenolic acid extract prepared in example 1, adding starch to 360g, filling into No. 1 capsules, and preparing into capsules, wherein the content of each capsule is 0.3 g.
Comparative example 6
Taking 60g of the total polypeptide extract, 80g of the total flavone extract and 40g of the total phenolic acid extract prepared in the example 1, adding starch to 360g, filling into No. 1 capsules, and preparing the capsules by 0.3g of the content of each capsule.
Comparative example 7
The capsule for treating asthma is prepared by the following formula: 120g of polysaccharide extract, 60g of total polypeptide extract, 80g of total flavone extract and 40g of total phenolic acid extract.
The difference from example 1 is that the total polysaccharide extract of comparative example 7 is extracted from a mixture of momordica grosvenori, tangerine peel and cuttlebone in a mass ratio of 1; total Polypeptides, total Flavonoids, and Total phenolic acid extract were as in example 1.
Adding starch to 360g of the above prescription medicine 300g, and encapsulating with number 1 capsule 0.3g of the content per capsule.
Experiment of
In order to further verify the pharmacological effects of the invention, animal pharmacodynamic experiments are carried out by using the capsules of the invention. The influence of the compound on the asthma of the mice is verified, and the research on the influence of the compound on the anti-inflammation and cough-relieving efficacy of the mice is focused.
1 reagents, samples and animals
1.1 reagents
Sodium chloride (AR), xylene (AR), picric Acid (AR), 25% concentrated Ammonia (AR), phenol red (AR) sodium hydroxide (AR), ammonium chloride (AR), 1mL syringe, mouse stomach syringe needle (12 # 55mm), surgical scissors, ophthalmological forceps, small test tube (5 mL)
1.2 test samples
The capsules obtained in example 1 and comparative examples 1 to 7 were used as the subjects.
Example 1 is labeled as sample 1, and comparative examples 1 to 5 are labeled as samples 2 to 8 in this order.
Control group: dingchuan Zhicouo Wan (Chinese medicine Standard Z20053992) from Tangshan Tongrentang Natural medicine (Tangshan).
Before administration, the corresponding preparation is taken, capsule content and cough relieving pills are taken, the mixture is ground, pure water is adopted to prepare a solution with the required medicine concentration of 2.6g/ml, and the administration dosage of the mouse is calculated to be intragastric 39.05 g/kg according to a conversion formula of the body surface area of the administration dosage of the mouse -1 ·d -1 ，。
1.3 Experimental animals
The Kunming white mouse has the weight of 18-22g and half of the male and female, and is provided by the experimental animal center of Shandong Chinese medicine university.
2 method of experiment
2.1 anti-inflammatory experiments
150 mice, each half of male and female, were randomly divided into blank control groups (liquid medicine is sterilized normal saline), sample 1 group, sample 2 group, sample 3 group, sample 4 group, sample 5 group, sample 6 group, sample 7 group, sample 8 group and control group, each group containing 15 mice, and fasted but not forbidden for 12h before the experiment. The gavage is carried out once a day, and the gavage is continuously carried out for 7 days. After the last gastric lavage for 30min for 1 time, 20 mu L of dimethylbenzene is respectively injected into the front and back sides of the right ear of the mouse by a pipette to cause the inflammation, and the left ear is not treated to be used as a self blank control. After 30min of inflammation, mice are sacrificed by adopting a cervical dislocation method, double ears are cut off, a puncher with the inner diameter of 6mm is used for punching wafers of corresponding parts of left and right ears, an analytical balance is used for weighing rapidly, the difference between the mass of the right ear piece and the mass of the left ear piece is used as swelling degree, swelling degree of each group is compared, and swelling inhibition rate is calculated: swelling inhibition rate = (negative control swelling degree-drug group swelling degree)/negative control swelling degree. The results are shown in Table 1.
TABLE 1 Effect of para-xylene induced auricle swelling in mice
2.2 cough-relieving experiment
150 mice, each half of male and female, were randomly divided into blank control groups (liquid medicine is sterilized normal saline), sample 1 group, sample 2 group, sample 3 group, sample 4 group, sample 5 group, sample 6 group, sample 7 group, and sample 8 group control groups, each group containing 15 mice, and fasted but not water-inhibited for 12h before the experiment. The gavage is carried out for 1 time every day and for 7 days continuously. And after the last 1-time intragastric administration for 1 hour, reversely covering a 1000mL big beaker on an experimental table, continuously spraying 25% concentrated ammonia water for 10s into the big beaker by using a sprayer, putting the mouse into the big beaker, starting timing, and recording the time for the mouse to cough for the first time and the cough frequency within 5min by taking abdominal muscle contraction, mouth-opening respiration and cough sound as indexes, wherein the experimental result is shown in table 2.
TABLE 2 inhibitory Effect on mouse cough caused by concentrated Ammonia Water
The test results show that the improvement of the sample 1 on inflammation diminishing and cough relieving is better than that of the samples 2, 3, 4 and 5, and the total condition of the sample 1 is more than that of the sample 2, the sample 3, the sample 4, the sample 5, the sample 6, the sample 7 and the sample 8 is more than that of the blank control. The selected combination ratio is better.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (9)
1. A traditional Chinese medicine effective part composition for treating asthma is characterized by comprising a total polysaccharide extract, a total polypeptide extract, a total flavone extract and a total phenolic acid extract;
the total polysaccharide extract is extracted from momordica grosvenori, red tangerine peel and cuttlebone, the total polypeptide extract is extracted from earthworm and mussel meat, the total flavone extract is extracted from pine pollen and poppy flower, and the total phenolic acid extract is extracted from myrobalan meat.
2. The traditional Chinese medicine effective part composition as claimed in claim 1, which comprises, by weight, 9 to 20 parts of total polysaccharide extract, 3 to 10 parts of total polypeptide extract, 6 to 12 parts of total flavone extract and 3 to 6 parts of total phenolic acid extract.
3. The traditional Chinese medicine effective part composition as claimed in claim 2, which comprises 12 parts by weight of total polysaccharides, 6 parts by weight of total polypeptides, 8 parts by weight of total flavonoids and 4 parts by weight of total phenolic acids.
4. The composition of the effective fractions of traditional Chinese medicine according to any one of claims 1 to 3, wherein the total polysaccharide content in the total polysaccharide extract is not less than 70wt%, the total polypeptide content in the total polypeptide extract is not less than 80wt%, and the total flavone content in the total flavone extract is not less than 40wt%.
5. The traditional Chinese medicine effective part composition according to claim 4, wherein the weight ratio of the momordica grosvenori, the exocarpium citri rubrum and the cuttlebone is 1: (1-3): (1-4).
6. The traditional Chinese medicine effective part composition according to claim 5, wherein the mass ratio of the momordica grosvenori to the exocarpium citri rubrum to the cuttlebone is 1:1.5:1.
7. a method for preparing the composition of the effective parts of the traditional Chinese medicine according to any one of claims 1 to 6, which comprises the following steps:
(1) Preparing a total polysaccharide extract: taking 4 parts by weight of momordica grosvenori, 6 parts by weight of exocarpium citri rubrum and 4 parts by weight of cuttlebone, adding 8-12 times of weight of water to extract for 1-3 times, each time for 2 hours, filtering, combining filtrates, concentrating under reduced pressure to 1g crude drug/mL, adding ethanol to the alcohol content of 50%, refrigerating and standing for 12 hours, filtering, continuously adding ethanol to the filtrate to the alcohol content of 80%, refrigerating and standing for 12 hours, collecting precipitate, repeatedly purifying the precipitate, adding 5-15 times of weight of water to fully dissolve, adding 0.5-5% of active carbon, keeping the temperature at 70-80 ℃ for decolorizing for 1-3 times, 0.5 hour/time, filtering, concentrating the filtrate under reduced pressure, and drying to obtain a total polysaccharide extract;
(2) Preparation of total polypeptide extract: taking 4 parts by weight of earthworms and 6 parts by weight of clam meat, adding 2-2.5 times of water by weight to homogenate to obtain meat pulp, adding 0.8% of papain, carrying out enzymolysis at 45 ℃ for 4 hours under the pH value of 6.5, after the enzymolysis reaction is finished, heating to 80-85 ℃, reacting for half an hour, standing at room temperature for 3 hours, and carrying out high-speed centrifugation at 12000r/min to obtain supernatant for spray drying to obtain a total polypeptide extract;
(3) Preparing a total flavone extract: taking 8 parts by weight of pine pollen and 2 parts by weight of poppy flower, adding 12-15 times of 70% ethanol by weight, extracting twice at 74-76 ℃ for 1.5 hours each time, concentrating the filtrate under reduced pressure, and drying to obtain a total flavone extract;
(4) Preparing a total phenolic acid extract: taking myrobalan pulp, adding 70% ethanol with the weight being 12-14 times of that of the myrobalan pulp, carrying out ultrasonic extraction for 2-3 times, combining filtrates, carrying out reduced pressure concentration, and drying to obtain a total phenolic acid extract.
8. The use of the composition of the effective fraction of a traditional Chinese medicine according to any one of claims 1 to 7 in the preparation of a medicament for treating asthma.
9. The use of claim 8, wherein the composition of the effective part of the traditional Chinese medicine is used as an effective component to prepare any one of tablets, granules, hard capsules, mixtures, pills, dripping pills, effervescent tablets, injections, powder injections or soft capsules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211465659.5A CN115813989A (en) | 2022-11-22 | 2022-11-22 | Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211465659.5A CN115813989A (en) | 2022-11-22 | 2022-11-22 | Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115813989A true CN115813989A (en) | 2023-03-21 |
Family
ID=85530175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211465659.5A Withdrawn CN115813989A (en) | 2022-11-22 | 2022-11-22 | Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115813989A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1167823A (en) * | 1997-03-25 | 1997-12-17 | 黄成已 | Method for producing health wine contg. compound active biological enzyme |
| CN102178022A (en) * | 2011-04-12 | 2011-09-14 | 郗定海 | Medicated candy capable of relieving asthma and sore throat and preparation method of the medicated candy |
| CN103330026A (en) * | 2013-06-14 | 2013-10-02 | 莫丕向 | Tea formula |
| CN105663362A (en) * | 2016-03-07 | 2016-06-15 | 广东美华农业生物科技有限公司 | Citri grandis decoction piece and preparation method thereof |
| CN107693576A (en) * | 2017-11-28 | 2018-02-16 | 孙志强 | A kind of Chinese medicine composition for being used to treat coronary heart disease |
| CN111213808A (en) * | 2018-11-27 | 2020-06-02 | 启东茂材实业有限公司 | Preparation method of compound lung-clearing effervescent tablets |
-
2022
- 2022-11-22 CN CN202211465659.5A patent/CN115813989A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1167823A (en) * | 1997-03-25 | 1997-12-17 | 黄成已 | Method for producing health wine contg. compound active biological enzyme |
| CN102178022A (en) * | 2011-04-12 | 2011-09-14 | 郗定海 | Medicated candy capable of relieving asthma and sore throat and preparation method of the medicated candy |
| CN103330026A (en) * | 2013-06-14 | 2013-10-02 | 莫丕向 | Tea formula |
| CN105663362A (en) * | 2016-03-07 | 2016-06-15 | 广东美华农业生物科技有限公司 | Citri grandis decoction piece and preparation method thereof |
| CN107693576A (en) * | 2017-11-28 | 2018-02-16 | 孙志强 | A kind of Chinese medicine composition for being used to treat coronary heart disease |
| CN111213808A (en) * | 2018-11-27 | 2020-06-02 | 启东茂材实业有限公司 | Preparation method of compound lung-clearing effervescent tablets |
Non-Patent Citations (1)
| Title |
|---|
| 孙丽平, 等: "王烈治疗小儿咳嗽验案", 中国社区医师, vol. 20, no. 21, pages 36 - 37 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016173509A1 (en) | Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof | |
| CN102258679B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN104887952B (en) | Composition with yin nourishing and lung moistening effects and preparation method and application thereof | |
| WO2018133563A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
| CN1970032B (en) | Chinese medicine containing honeysuckle flower and weeping forsythia for treating cold | |
| RU2519672C2 (en) | Traditional chinese medical composition for treating bronchial asthma and method for preparing it | |
| CN106361993A (en) | Medicinal composition for preventing and treating gastric mucosal lesion and preparation method of medicinal composition | |
| CN101396528B (en) | Traditional Chinese medicine composite preparation for treating wind-heat cold | |
| CN112494598B (en) | Effective part composition for treating pharyngitis and application thereof | |
| CN104286844B (en) | A kind of improve the food of immunity, health product or pharmaceutical composition | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN1709299A (en) | Chinese medicine formulation for treating asthma and its preparing method | |
| CN115813989A (en) | Traditional Chinese medicine effective part composition for treating asthma and preparation method and application thereof | |
| CN101396435B (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN112716998B (en) | Traditional Chinese medicine preparation for treating pulmonary hypertension | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| AU2019100737A4 (en) | Anti-Helicobacter Pylori Traditional Chinese Medicine composition and applications | |
| CN102988422A (en) | American cockroach nano extract and preparation method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN112245527A (en) | Preparation method of active polysaccharide extract, functional beverage and effervescent granule with homology of medicine and food | |
| CN105963410B (en) | Traditional Chinese medicine composition with cough relieving function and preparation thereof | |
| CN111821325A (en) | Application of photorhaponticum flower extract | |
| CN102370903B (en) | Pharmaceutical composition for treating nephrosis and preparation method thereof | |
| CN110237110B (en) | Acanthopanax senticosus extract and extraction method and application thereof | |
| CN110721201B (en) | Application of tortoise-shell glue in preparing medicine for treating chronic heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230321 |
|
| WW01 | Invention patent application withdrawn after publication |